PNC-27 is a chimeric peptide designed for selective anti-cancer activity. It exploits the fact that certain cancer cells display HDM2 on their surface, providing a target for selective membrane disruption.
Research Applications
Anti-tumor mechanism research, selective membranolysis, HDM2 biology, and cancer cell targeting studies.
Dosage Information (Research Use)
Primarily studied in vitro. In vivo dosing protocols limited. Research use only.
Reconstitution & Handling
Standard BAC water reconstitution.
Half-Life & Pharmacokinetics
Not well characterized.
Reported Observations in Literature
No significant toxicity to normal cells in vitro. In vivo safety data limited.
Key Research References
- Kanovsky M, et al. “Peptides from the amino terminal mdm-2-binding domain of p53 carry an anti-neoplastic signal.” Oncogene. 2001